|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 39/395 | |
| C07K 16/22 | |||
| G01N 33/53 | |||
| C12N 15/68 | |||
| C12N 5/10 | |||
| A61P 25/00 | |||
| A61P 35/00 | |||
| A61P 19/02 | |||
| A61P 29/02 |
| (11) | Number of the document | 2485760 |
| (13) | Kind of document | T |
| (96) | European patent application number | 10766193.6 |
| Date of filing the European patent application | 2010-10-08 | |
| (97) | Date of publication of the European application | 2012-08-15 |
| (45) | Date of publication and mention of the grant of the patent | 2016-07-13 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2010/051960 |
| Date | 2010-10-08 |
| (87) | Number | WO 2011/049758 |
| Date | 2011-04-28 |
| (30) | Number | Date | Country code |
| 576522 | 2009-10-09 | US |
| (72) |
WILD, Kenneth, D., US
TREANOR, James, J.s., US
HUANG, Haichun, US
INOUE, Heather, US
ZHANG, Tie, J., US
MARTIN, Frank, US
|
| (73) |
Amgen, Inc,
One Amgen Center Drive, Thousand Oaks, CA 91320-1799,
US
E. R. Squibb & Sons, L.L.C., Route 206 & Province Line Road, Princeton, NJ 08540, US |
| (54) | HUMAN ANTI-NGF NEUTRALIZING ANTIBODIES AS SELECTIVE NGF PATHWAY INHIBITORS |
| HUMAN ANTI-NGF NEUTRALIZING ANTIBODIES AS SELECTIVE NGF PATHWAY INHIBITORS |